Search

Your search keyword '"Möbus, V"' showing total 456 results
Start Over Author "Möbus, V"
456 results on '"Möbus, V"'

157. Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125, and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass: An International Multicenter Study

Author

Schutter, E.M.J., primary, Sohn, C., additional, Kristen, P., additional, Möbus, V., additional, Crombach, G., additional, Kaufmann, M., additional, Caffier, H., additional, Kreienberg, R., additional, Verstraeten, A.A., additional, and Kenemans, P., additional

Published
1998
Full Text
View/download PDF

158. P92 Low morbidity and no mortality of high-dose cyclophosphamide, thiotepa and mitoxantrone plus autologous peripheral blood stem cell support for high-risk breast cancer patients

Author

Kröger, N., primary, Krüger, W.H., additional, Gieseking, F., additional, Jaenicke, F., additional, Schultze, W., additional, Fuss, H., additional, Möbus, V., additional, Königsmann, M., additional, Berdel, W.E., additional, Schäfer-Eckert, K., additional, Wandt, H., additional, Metzner, B., additional, Illiger, H.J., additional, Frickhofen, N., additional, Wulf, G., additional, Wörmann, B., additional, Kolbe, K., additional, Hossfeld, D.K., additional, Maas, H., additional, Jonat, W., additional, and Zander, A.R., additional

Published
1998
Full Text
View/download PDF

185. Effects of interferon γ on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines.

Author

Möbus, V., Asphal, W., Knapstein, P., and Kreienberg, R.

Abstract

Platinum-containing regimens are very effective in the primary treatment of ovarian cancer. However, upon subsequent treatment most tumors develop multidrug resistance. The clinical application of biological response modifiers like interferon γ (IFNγ) in advanced ovarian cancer is therefore of increasing interest. Permanent ovarian cancer cell lines are suitable for investigating the mode of action and the potential clinical effectiveness of such response modifiers. IFNγ is known to modulate many cellular functions. In this study it was compared for its antiproliferative and antigen-modulatory activity on the expression of tumor-associated (CA-125, HMFG, CEA) and major histocompatibility complex (MHC) class I and II antigens as well as of the epidermal growth factor (EGF) receptor on 20 newly established human ovarian carcinoma cell lines. IFNγ in concentrations of 10, 50 and 100 U/ml was used to study its antigen-modulatory effect, and at additional 1 U/ml and 1000 U/ml to assess its antiproliferative effect on the cells. The cells were incubated with IFN for 4 days. Two cell lines showed strong antiproliferative activity even at minimal doses (up to 50 U/ml). Intermediate growth inhibition between 34% and 84% was observed in 15 cell lines with higher doses. Three lines were resistant to IFNγ. Independent of the antiproliferative effect, IFNγ enhanced the expression of MHC class I and MHC class II in nearly all cell lines. Upregulation was also observed for most of the tumor-associated antigens (TAA) and EGF receptor expression. A downregulation was noticed but rarely. The fact that IFNγ showed an antiproliferative activity on the majority of the cell lines is of clinical relevance. The in vitro modulation of cell-surface determinants by IFNγ warrants special attention. The enhanced expression of TAA and MHC antigens can improve immunogenicity of the tumor cells and may explain the therapeutic effects observed under IFN therapy in ovarian cancer. By contrast, enhanced expression of the EGF receptor, often associated with poor patient survival rates, may be an undesirable side-effect of IFN therapy. [ABSTRACT FROM AUTHOR]

Published
1994
Full Text
View/download PDF

190. In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells

Author

Stoeck, M., Marland-Noske, C., Manasterski, M., Zawatzky, R., Horn, S., Möbus, V., Schlag, P., and Schirrmacher, V.

Abstract

In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability >0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCRaß (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon ? and tumour necrosis factor a was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.

Published
1993
Full Text
View/download PDF

191. Effects of interferon γ on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines

Author

Möbus, V. J., Asphal, W., Knapstein, P. G., and Kreienberg, R.

Abstract

Platinum-containing regimens are very effective in the primary treatment of ovarian cancer. However, upon subsequent treatment most tumors develop multidrug resistance. The clinical application of biological response modifiers like interferon ? (IFN?) in advanced ovarian cancer is therefore of increasing interest. Permanent ovarian cancer cell lines are suitable for investigating the mode of action and the potential clinical effectiveness of such response modifiers. IFN? is known to modulate many cellular functions. In this study it was compared for its antiproliferative and antigen-modulatory activity on the expression of tumor-associated (CA-125, HMFG, CEA) and major histocompatibility complex (MHC) class I and II antigens as well as of the epidermal growth factor (EGF) receptor on 20 newly established human ovarian carcinoma cell lines. IFN? in concentrations of 10, 50 and 100 U/ml was used to study its antigen-modulatory effect, and at additional 1 U/ml and 1000 U/ml to assess its antiproliferative effect on the cells. The cells were incubated with IFN for 4 days. Two cell lines showed strong antiproliferative activity even at minimal doses (up to 50 U/ml). Intermediate growth inhibition between 34% and 84% was observed in 15 cell lines with higher doses. Three lines were resistant to IFN?. Independent of the antiproliferative effect, IFN? enhanced the expression of MHC class I and MHC class II in nearly all cell lines. Upregulation was also observed for most of the tumor-associated antigens (TAA) and EGF receptor expression. A downregulation was noticed but rarely. The fact that IFN? showed an antiproliferative activity on the majority of the cell lines is of clinical relevance. The in vitro modulation of cell-surface determinants by IFN? warrants special attention. The enhanced expression of TAA and MHC antigens can improve immunogenicity of the tumor cells and may explain the therapeutic effects observed under IFN therapy in ovarian cancer. By contrast, enhanced expression of the EGF receptor, often associated with poor patient survival rates, may be an undesirable side-effect of IFN therapy.

Published
1993
Full Text
View/download PDF

192. Monoklonale Antikörper in Diagnostik und Verlaufskontrolle des Ovarialkarzinoms. CA 125 als Tumormarker

Author

Kaesemann, H., Caffier, H., Hoffmann, F. J., Crombach, G., Würz, H., Kreienberg, R., Möbus, V., Schmidt-Rhode, P., and Sturm, G.

Abstract

Summary The clinical validity of using the cancer antigen (CA) 125 — a surface antigen on malignant epithelial ovarian tumors — for diagnosis and follow-up of ovarian cancer was investigated in a cooperative study. Using a monoclonal antibody (OC 125) to detect CA 125, the sera of 850 patients were analyzed by immunoradiometric assay (IRMA-Kit Centocor).

Published
1986
Full Text
View/download PDF

193. Expression of pS2 protein in breast cancer

Author

Crombach, G., Ingenhorst, A., Göhring, U. -J., Scharl, A., Neuhaus, W., Möbus, V., and Schaeffer, H. -J.

Abstract

The pS2 protein was first detected in the oestrogen-dependent breast cancer cell line MCF-7. It may have prognostic value for primary breast cancer, and could be used to predict clinical responsiveness to endocrine therapy. In a retrospective study, the concentrations of pS2 protein were determined in 434 cytosol specimens using an immunoradiometric assay. The median values (4, 6 and 3 ng/mg protein) and the third quartiles (27, 26 and 29 ng/mg) in benign breast tumours (n=17), and in primary (n=325) and recurrent (n=37) breast carcinomas were of the same order of magnitude. In primary breast cancer, high pS2 values (>26 ng/mg) correlated significantly with a positive oestrogen receptor (ER) status and a high grade of tumour differentiation (P=0.01). As many as 85% of the pS2 positive tumours were ER positive. A marginally significant correlation (P=0.06) was also found between pS2 status and the quantitative expression of the ER. However, the pS2 values in ER positive endometrial carcinomas (n=12) as well as in other benign and malignant genital tumours (n=43) were more than 30 times lower than those measured in breast tumours. The results reveal a close association between pS2 protein and ER status which appears to be limited to breast cancer.

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results